Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
11 trends tracked about this subject — the full history, oldest to newest below.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Cerevance secures a pivotal phase 3 trial win, rescuing its Parkinson's disease drug and inspiring new hope in patients.
Fierce Biotech has unveiled its 2026 'Fierce 15' list, highlighting the most innovative and promising private biotechnology companies of the year.
Foghorn Therapeutics cuts 40% of staff after Eli Lilly ends a cancer collaboration due to poor data.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Scientists and journal editors have launched a boycott of the American Diabetes Association following a June conference incident.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Recent studies and reports indicate that artificial intelligence is delivering substantial cost savings and efficiency to oncology clinical trials.
Biogen defends its anti-tau drug following a stock decline triggered by a recent Alzheimer's treatment readout.
Coverage from multiple industry outlets explores how engineered immune therapies and checkpoint inhibitors are transforming cancer treatment.